May 25, 2017: ALS Biopharma, LLC is pleased to announce that the U.S. Food and Drug Administration (FDA) has provided fast-track designation to trigriluzole for the treatment of ataxia. Trigriluzole, also known as FC-4157 and BHV-4157, is an investigational new drug being developed by Biohaven Pharmaceutical Holding Company Ltd.

July 5, 2016: ALS Biopharma, LLC is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its review of the FC-4157 (also known as BHV-4157) investigational new drug application (IND) filed on May 31, 2016 by Biohaven Pharmaceutical Holding Company Ltd.

August 18, 2015: ALS Biopharma announces a new research collaboration with Biohaven for the development of certain prodrugs, as described in a press release.

August 21, 2014: ALS Biopharma announces it has been granted an exclusive license to Riluzole Prodrug technology originally developed by Fox Chase Chemical Diversity Center Inc.

March 13, 2013: ALS Biopharma announces the addition to its Scientific Advisory Board three world-class experts in the area of ALS research.

December 19, 2012: ALS Biopharma announces that is has been awarded a KIZ tax credit of $40,140 from the Commonwealth of Pennsylvania.

March 8, 2012:. ALS Biopharma announces that it has been awarded a KIZ tax credit of $100,000 from the Commonwealth of Pennsylvania.

October 7, 2011: ALS Biopharma announces that it has been named the Gold Best Early-Stage Company award winner by the Philadelphia Business Journal

September 6, 2011: ALS Biopharma announces that it was been selected as a finalist in the Philadelphia Business Journal Life Sciences Award program.

March 24, 2011: ALS Biopharma is pleased to announce that the company has been granted orphan drug designationby the U.S. Food and Drug Administration for heat shock protein Hsp70 for the treatment of amyotrophic lateral sclerosis.

March 11, 2011: ALS Biopharma, LLC reports that MDA Venture Philanthropy has awarded the company a grant of $250,000.

March 1, 2011: ALS Biopharma is proud to annouce the award of NIH grant R21NS072749-02, titled Small Molecule Probes for TAR DNA Binding Protein 43_TDP-43.

January 27, 2011: Alzheimer's Drug Discovery Foundation Funds ALS Biopharma, LLC to Develop Small Molecules for Alzheimer's Disease